Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model
Edward J Meier,1 Gail L Torkildsen,2 Paul J Gomes,3 Mark C Jasek4 1Apex Eye, Mason, OH, USA; 2Andover Eye, Andover, MA, USA; 3Allergy, Ora, Inc., Andover, MA, USA; 4Eyevance Pharmaceuticals, TX, USA Purpose: The purpose of these Phase III studies was to evaluate the efficacy and safety of cetirizi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-12-01
|
| Series: | Clinical Ophthalmology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/phase-iii-trials-examining-the-efficacy-of-cetirizine-ophthalmic-solut-peer-reviewed-article-OPTH |
| _version_ | 1818998981433229312 |
|---|---|
| author | Meier EJ Torkildsen GL Gomes PJ Jasek MC |
| author_facet | Meier EJ Torkildsen GL Gomes PJ Jasek MC |
| author_sort | Meier EJ |
| collection | DOAJ |
| description | Edward J Meier,1 Gail L Torkildsen,2 Paul J Gomes,3 Mark C Jasek4 1Apex Eye, Mason, OH, USA; 2Andover Eye, Andover, MA, USA; 3Allergy, Ora, Inc., Andover, MA, USA; 4Eyevance Pharmaceuticals, TX, USA Purpose: The purpose of these Phase III studies was to evaluate the efficacy and safety of cetirizine ophthalmic solution 0.24% compared with vehicle in the treatment of allergen-induced conjunctivitis using the Ora conjunctival allergen challenge (CAC)® model.Methods: The single-center (Study 1) and multi-center (Study 2), double-masked, randomized, vehicle-controlled, parallel group, CAC studies were conducted over ~5 weeks and four study visits. The study design only differed in entry criteria: Study 2 required more severe allergic conjunctivitis symptoms. Subjects were screened for an allergen response at Visits 1 and 2 and then randomized at Visit 3. Approximately 100 subjects were randomized in each study. The primary efficacy endpoints were ocular itching and conjunctival redness 15 minutes and 8 hours post-treatment, post-CAC.Results: Cetirizine treatment administered 15 minutes or 8 hours prior to CAC resulted in significantly lower ocular itching at all time points post-CAC (P<0.0001) compared to vehicle in both studies. Conjunctival redness measured by the investigator was significantly lower after cetirizine treatment compared to vehicle at 7 minutes post-CAC at both 15 minutes and 8 hours post-treatment in both studies (P<0.05). All secondary endpoints were in favor and confirmatory of cetirizine efficacy with significant improvement in chemosis, eyelid swelling, tearing, ciliary redness, and episcleral redness, as well as nasal symptoms (rhinorrhea, nasal pruritus, ear or palatal pruritus, and nasal congestion) post-CAC. The most robust treatment differences were observed in Study 2 where more severe symptoms were required for study entry (P<0.05). No safety concerns for cetirizine ophthalmic solution 0.24% were identified.Conclusion: Cetirizine ophthalmic solution 0.24% was shown to be efficacious in the treatment of ocular and nasal signs and symptoms associated with allergic conjunctivitis and demonstrated a favorable safety profile. Clinical efficacy was demonstrated with a 15-minute onset of action and an ~8-hour duration of action. Keywords: ocular allergy, cetirizine, ocular itching, safety, topical administration |
| first_indexed | 2024-12-20T22:10:10Z |
| format | Article |
| id | doaj.art-dd456f467fde4c778cdab3f61ac7aca1 |
| institution | Directory Open Access Journal |
| issn | 1177-5483 |
| language | English |
| last_indexed | 2024-12-20T22:10:10Z |
| publishDate | 2018-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Ophthalmology |
| spelling | doaj.art-dd456f467fde4c778cdab3f61ac7aca12022-12-21T19:25:11ZengDove Medical PressClinical Ophthalmology1177-54832018-12-01Volume 122617262843027Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge modelMeier EJTorkildsen GLGomes PJJasek MCEdward J Meier,1 Gail L Torkildsen,2 Paul J Gomes,3 Mark C Jasek4 1Apex Eye, Mason, OH, USA; 2Andover Eye, Andover, MA, USA; 3Allergy, Ora, Inc., Andover, MA, USA; 4Eyevance Pharmaceuticals, TX, USA Purpose: The purpose of these Phase III studies was to evaluate the efficacy and safety of cetirizine ophthalmic solution 0.24% compared with vehicle in the treatment of allergen-induced conjunctivitis using the Ora conjunctival allergen challenge (CAC)® model.Methods: The single-center (Study 1) and multi-center (Study 2), double-masked, randomized, vehicle-controlled, parallel group, CAC studies were conducted over ~5 weeks and four study visits. The study design only differed in entry criteria: Study 2 required more severe allergic conjunctivitis symptoms. Subjects were screened for an allergen response at Visits 1 and 2 and then randomized at Visit 3. Approximately 100 subjects were randomized in each study. The primary efficacy endpoints were ocular itching and conjunctival redness 15 minutes and 8 hours post-treatment, post-CAC.Results: Cetirizine treatment administered 15 minutes or 8 hours prior to CAC resulted in significantly lower ocular itching at all time points post-CAC (P<0.0001) compared to vehicle in both studies. Conjunctival redness measured by the investigator was significantly lower after cetirizine treatment compared to vehicle at 7 minutes post-CAC at both 15 minutes and 8 hours post-treatment in both studies (P<0.05). All secondary endpoints were in favor and confirmatory of cetirizine efficacy with significant improvement in chemosis, eyelid swelling, tearing, ciliary redness, and episcleral redness, as well as nasal symptoms (rhinorrhea, nasal pruritus, ear or palatal pruritus, and nasal congestion) post-CAC. The most robust treatment differences were observed in Study 2 where more severe symptoms were required for study entry (P<0.05). No safety concerns for cetirizine ophthalmic solution 0.24% were identified.Conclusion: Cetirizine ophthalmic solution 0.24% was shown to be efficacious in the treatment of ocular and nasal signs and symptoms associated with allergic conjunctivitis and demonstrated a favorable safety profile. Clinical efficacy was demonstrated with a 15-minute onset of action and an ~8-hour duration of action. Keywords: ocular allergy, cetirizine, ocular itching, safety, topical administrationhttps://www.dovepress.com/phase-iii-trials-examining-the-efficacy-of-cetirizine-ophthalmic-solut-peer-reviewed-article-OPTHAllergic conjunctivitiscetirizineocular itchingsafetytopical administration |
| spellingShingle | Meier EJ Torkildsen GL Gomes PJ Jasek MC Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model Clinical Ophthalmology Allergic conjunctivitis cetirizine ocular itching safety topical administration |
| title | Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model |
| title_full | Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model |
| title_fullStr | Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model |
| title_full_unstemmed | Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model |
| title_short | Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model |
| title_sort | phase iii trials examining the efficacy of cetirizine ophthalmic solution 0 24 compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model |
| topic | Allergic conjunctivitis cetirizine ocular itching safety topical administration |
| url | https://www.dovepress.com/phase-iii-trials-examining-the-efficacy-of-cetirizine-ophthalmic-solut-peer-reviewed-article-OPTH |
| work_keys_str_mv | AT meierej phaseiiitrialsexaminingtheefficacyofcetirizineophthalmicsolution024comparedtovehicleforthetreatmentofallergicconjunctivitisintheconjunctivalallergenchallengemodel AT torkildsengl phaseiiitrialsexaminingtheefficacyofcetirizineophthalmicsolution024comparedtovehicleforthetreatmentofallergicconjunctivitisintheconjunctivalallergenchallengemodel AT gomespj phaseiiitrialsexaminingtheefficacyofcetirizineophthalmicsolution024comparedtovehicleforthetreatmentofallergicconjunctivitisintheconjunctivalallergenchallengemodel AT jasekmc phaseiiitrialsexaminingtheefficacyofcetirizineophthalmicsolution024comparedtovehicleforthetreatmentofallergicconjunctivitisintheconjunctivalallergenchallengemodel |